Lixisenatide


GLP-1 receptor agonist

A daily-dosing GLP-1 receptor agonist FDA-approved 2016 (Adlyxin) for T2DM, structurally derived from exenatide.

Abstract

Lixisenatide (Adlyxin, Lyxumia; CAS 320367-13-3; molecular weight 4858.49) is a 44-amino-acid peptide GLP-1 receptor agonist developed by Sanofi and approved by the FDA in 2016 for T2DM. The compound is structurally derived from exenatide with a six-lysine C-terminal extension. Pharmacokinetics: plasma half-life ~3 hours; once-daily dosing.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph